Ann Surg Treat Res.  2024 Dec;107(6):327-335. 10.4174/astr.2024.107.6.327.

Prognostic implications of ductal carcinoma in situ components in BRCA1/2-positive breast cancer: a retrospective cohort study

• Yoon KH
• Kim EK
• Shin HC

• KMID: 2562308
• DOI: http://doi.org/10.4174/astr.2024.107.6.327

Abstract

Purpose
Although the breast cancer susceptibility gene (BRCA)-associated invasive breast cancer is well studied, there are limited reports on ductal carcinoma in situ (DCIS) in patients with BRCA1/2 mutations. This study aims to evaluate the differential prognostic effect of DCIS in breast cancer patients with pathologic variants of BRCA1/2 genes.
Methods
Breast cancer patients who tested positive for BRCA1/2 mutations between August 2003 and January 2022 at a single tertiary referral center were retrospectively analyzed. Survival outcomes were compared between patients with both invasive ductal carcinoma (IDC) and DCIS (IDC-DCIS group, n = 121) and those with IDC alone (IDC group, n = 36).
Results
Of the 157 patients, 65 (41.4%) exhibited mutations in BRCA, 90 (57.3%) in BRCA2, and 2 (1.3%) in both BRCA1/2. DCIS components were more frequently found in BRCA2 pathological variants (BRCA, 46 [38.0%] vs. BRCA2, 76 [62.4%]; P = 0.030). No statistically significant difference was found in 10-year recurrence-free survival (IDC-DCIS, 89.3% vs. IDC, 83.6%; P = 0.989). Subgroup analysis indicated that the DCIS component correlated with improved survival outcomes in the BRCA1 subgroup (BRCA1 IDC-DCIS, 85.5% vs. BRCA1 IDC, 51.0%; P = 0.024). Conversely, in the BRCA2 subgroup, IDCDCIS patients exhibited a worse prognosis (BRCA1 IDC-DCIS, 85.5% vs. BRCA2 IDC-DCIS, 65.8%; P = 0.045).
Conclusion
The presence of a DCIS component carries varied prognostic significance in BRCA1 and BRCA2 mutations. A tailored approach may be necessary when determining treatment options for breast cancer patients with BRCA1/2 mutations based on the presence of DCIS.

Keyword

Breast neoplasms; BRCA1 protein; BRCA2 protein; Breast carcinoma in situ

Figure

• 

  Fig. 1 Disease-free survival according to the presence of ductal carcinoma in situ component. (A) All patients. (B) BRCA1 subgroup. (C) BRCA2 subgroup. IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ.

• 

  Fig. 2 Disease-free survival according to BRCA mutation type and presence of DCIS component. IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ. *P = 0.821, **P = 0.045, †P = 0.024.

Reference

1. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001; 358:1389–1399. PMID: 11705483.

2. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002; 86:76–83. PMID: 11857015.

3. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994; 266:120–122. PMID: 7939630.

4. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266:66–71. PMID: 7545954.

5. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72:1117–1130. PMID: 12677558.

6. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25:1329–1333. PMID: 17416853.

7. Moyer VA. U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160:271–281. PMID: 24366376.

8. Elezaby M, Lees B, Maturen KE, Barroilhet L, Wisinski KB, Schrager S, et al. BRCA mutation carriers: breast and ovarian cancer screening guidelines and imaging considerations. Radiology. 2019; 291:554–569. PMID: 31038410.

9. Seki A, Tsunoda H, Takei J, Suzuki M, Kanomata N, Yamauchi H. Clinicopathological and imaging features of ductal carcinoma in situ in BRCA1/2 mutation carriers. Breast Dis. 2023; 42:5–15. PMID: 36806499.

10. Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005; 293:964–969. PMID: 15728167.

11. Wu SG, Zhang WW, Sun JY, He ZY. Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis. Cancer Manag Res. 2018; 10:527–534. PMID: 29593431.

12. Cedolini C, Bertozzi S, Londero AP, Seriau L, Andretta M, Agakiza D, et al. Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer. Int J Clin Exp Pathol. 2015; 8:13304–13313. PMID: 26722534.

13. Dzierzanowski M, Melville KA, Barnes PJ, MacIntosh RF, Caines JS, Porter GA. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins. J Surg Oncol. 2005; 90:71–76. PMID: 15844190.

14. Lee WP, Shetty SS, Seah CM, Tan PT, Tan SM. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: an Asian perspective. Cancer Rep (Hoboken). 2022; 5:e1646. PMID: 35892151.

15. Papantoniou V, Sotiropoulou E, Valsamaki P, Tsaroucha A, Sotiropoulou M, Ptohis N, et al. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade. Breast Cancer. 2011; 18:286–291. PMID: 20143189.

16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147:573–577. PMID: 17938396.

17. Liu Y, Ide Y, Inuzuka M, Tazawa S, Kanada Y, Matsunaga Y, et al. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. Mol Genet Genomic Med. 2019; 7:e493. PMID: 30652428.

18. Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol. 2007; 25:642–647. PMID: 17210933.

19. Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer. 1998; 83:2335–2345. PMID: 9840533.

20. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998; 90:1138–1145. PMID: 9701363.

21. Faermann R, Friedman E, Kaidar-Person O, Weidenfeld J, Brodsky M, Shalmon A, et al. Ductal carcinoma in situ (DCIS) diagnosed by MRI-guided biopsy among BRCA1/BRCA2 mutation carriers. Breast J. 2022; 2022:4317693. PMID: 36349178.

22. Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, et al. DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3. J Transl Med. 2015; 13:335. PMID: 26496879.

23. Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, et al. Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ: a nested case-control study. Clin Cancer Res. 2018; 24:3593–3601. PMID: 29685879.

24. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res. 2005; 25(3A):1719–1723. PMID: 16033090.

25. Kim JY, Han W, Moon HG, Park IA, Ahn SK, Kim J, et al. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor. Clin Breast Cancer. 2013; 13:385–391. PMID: 23870857.

26. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346:1609–1615. PMID: 12023992.

27. Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002; 359:1471–1477. PMID: 11988246.

28. Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014; 144:443–455. PMID: 24567198.

29. Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, et al. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019; 175:443–449. PMID: 30756284.

30. Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016; 34:3308–3314. PMID: 27480155.